Baidu
map

Eur J Nucl Med Mol Imaging:诊断恶性胸腔积液的PET-CT评分

2019-04-10 不详 北京朝阳医院

近日,首都医科大学附属北京朝阳医院施焕中教授团队在《European Journal of Nuclear Medicine and Molecular Imaging》上发表题为"Development and validation of the PET-CT score for diagnosis of malignant pleural effusion"的论文。研究团队经过临床研究,提出诊

近日,首都医科大学附属北京朝阳医院施焕中教授团队在《European Journal of Nuclear Medicine and Molecular Imaging》上发表题为"Development and validation of the PET-CT score for diagnosis of malignant pleural effusion"的论文。研究团队经过临床研究,提出诊断恶性胸腔积液的PET-CT评分。

恶性胸腔积液(MPE)常见于多种恶性肿瘤的晚期,肺癌是最常见病因。国外报道细胞学诊断的阳性率一般为60%(40%-87%),说明MPE在诊断方面存在诸多挑战。早在1997年,比利时呼吸科医师Bury等首次提出PET诊断MPE的临床价值。后续大量相关研究证实,PET-CT单个指标对于鉴别诊断具有一定的参考价值,由于敏感度和特异度不高而无法满足临床的实际需要。因此,施焕中教授团队探讨联合应用多种PET-CT指标构建评分系统(PET/CT评分),以期提高MPE的诊断效率。

从2014年5月1日至2015年10月31日,研究团队搜集整理大量病例,开始关于PET-CT诊断恶性胸腔积液(MPE)的研究,6个月之后开始进行随访。研究团队首先应用单变量分析的方法对29个PET-CT参数进行评估,发现其中19个参数具有统计学意义。随后,应用多变量Logistic回归模型进一步分析这19个变量,最终筛选出5个变量构建PET-CT评分系统,加权结果如下:1.伴18F-FDG摄取增强的单侧肺部结节和/或肿块(3分);2.肺外原发/转移恶性肿瘤(3分);3.伴18F-FDG摄取增强的胸膜增厚(2分);4.伴18F-FDG摄取增强的肺多发结节或肿块(1分);5.胸腔积液18F-FDG摄取增强(1分)。

在推导队列(n=199)中,PET-CT评分的最高值为10分。经ROC分析取最佳临界值4分,PET-CT评分诊断MPE的敏感度为83.3%,特异度为92.2%,阳性似然比为10.7,阴性似然比为0.2,AUC为0.949。结果表明,PET-CT评分为MPE患者提供较为理想的诊断效率,明显优于任何一个单独的PET-CT参数。上述诊断指标在验证队列(n=75)得到了进一步的证实。此外,研究结果还显示,上述5个参数中的任何一个对于鉴别这段MPE都具有一定的参考价值。虽然这些参数无一能单独满足临床环境中的诊断目的,但是若成组观察则可见有意义的结果。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1727965, encodeId=48941e2796527, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 23 07:12:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331128, encodeId=2352133112866, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426268, encodeId=928f1426268fe, content=<a href='/topic/show?id=a4ef140e620' target=_blank style='color:#2F92EE;'>#PET-CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14076, encryptionId=a4ef140e620, topicName=PET-CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21cd4047192, createdName=saikp, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506790, encodeId=0ecd1506e9074, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609689, encodeId=d4de160968954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=)]
    2019-06-23 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1727965, encodeId=48941e2796527, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 23 07:12:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331128, encodeId=2352133112866, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426268, encodeId=928f1426268fe, content=<a href='/topic/show?id=a4ef140e620' target=_blank style='color:#2F92EE;'>#PET-CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14076, encryptionId=a4ef140e620, topicName=PET-CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21cd4047192, createdName=saikp, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506790, encodeId=0ecd1506e9074, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609689, encodeId=d4de160968954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1727965, encodeId=48941e2796527, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 23 07:12:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331128, encodeId=2352133112866, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426268, encodeId=928f1426268fe, content=<a href='/topic/show?id=a4ef140e620' target=_blank style='color:#2F92EE;'>#PET-CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14076, encryptionId=a4ef140e620, topicName=PET-CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21cd4047192, createdName=saikp, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506790, encodeId=0ecd1506e9074, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609689, encodeId=d4de160968954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=)]
    2019-04-12 saikp
  4. [GetPortalCommentsPageByObjectIdResponse(id=1727965, encodeId=48941e2796527, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 23 07:12:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331128, encodeId=2352133112866, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426268, encodeId=928f1426268fe, content=<a href='/topic/show?id=a4ef140e620' target=_blank style='color:#2F92EE;'>#PET-CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14076, encryptionId=a4ef140e620, topicName=PET-CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21cd4047192, createdName=saikp, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506790, encodeId=0ecd1506e9074, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609689, encodeId=d4de160968954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1727965, encodeId=48941e2796527, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 23 07:12:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331128, encodeId=2352133112866, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426268, encodeId=928f1426268fe, content=<a href='/topic/show?id=a4ef140e620' target=_blank style='color:#2F92EE;'>#PET-CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14076, encryptionId=a4ef140e620, topicName=PET-CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21cd4047192, createdName=saikp, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506790, encodeId=0ecd1506e9074, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609689, encodeId=d4de160968954, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 12 11:12:00 CST 2019, time=2019-04-12, status=1, ipAttribution=)]

相关资讯

2018 ERS/EACTS声明:恶性胸腔积液的管理

恶性胸腔积液是一种常见的病理状态,主要由呼吸科科胸外科医生管理。本文为ERS联合EACTS共识制定的关于恶性胸腔积液的管理声明,主要涉及6个方面的内容,包括胸腔积液的症状管理,肺萎陷的管理,包裹性胸腔积液的管理,预后因素组织学诊断等。

CHEST:复发性恶性胸腔积液应如何治疗与管理?

目前的指南对复发性恶性胸腔积液(MPE)的管理推荐了一些做法,如留置胸膜导管(IPC)或胸膜固定术,这些方法优于重复的胸腔穿刺术。近期,一项发表在杂志CHEST上的研究评估了患者没有根据指南的推荐而是进行多次胸腔穿刺后是否导致更多的手术和并发症的发生。此项研究为回顾性队列研究,选取了2007-2011年SEER-Medicare的数据。研究人群为66-90岁的MPE患者。此项研究的主要结果是,快速

Lancet Respir Med:留置胸导管(AMPLE-2)对恶性胸腔积液进行激进性和症状引导性引流的比较

研究发现,在控制呼吸困难方面,用于留置胸导管的激进引流(每日)和症状引导引流方案之间没有差异。

2018 ATS/STS/STR临床实践指南:恶性胸腔积液的管理

2018年10月,美国胸科学会(ATS)、美国胸外科医师学会(STS)以及美国胸部放射学学会(STR)联合发布了恶性胸腔积液的管理指南,主要目的是针对恶性胸腔积液患者的管理提供循证指导建议,文章共针对7个PICO问题提出建议。

重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识

恶性胸、腹腔积液是晚期恶性肿瘤最常见的并发症之一,预后较差,临床上缺乏公认的标准治疗药物和方案。重组改构人肿瘤坏死因子( rmhTNF,天恩福) 为肿瘤生物免疫治疗药物,经过临床试验,2004 年获得国家食品药品监督管理总局( CFDA) 批准,作为国家一类生物制品在国内上市; 主要用于单药或联合化疗治疗复发难治的非小细胞肺癌( NSCLC)和非霍奇金淋巴瘤( NHL) 。注册临床研究和上市后IV

2018美恶性胸腔积液指南:无呼吸困难等症状,则无须胸腔穿刺排液

近期,美国胸科学会(ATS)、美国胸外科医师学会(STS)以及美国胸部放射学学会(STR)联合发布了恶性胸腔积液(MPE)的管理指南。该指南提出并回答了恶性胸腔积液临床管理中存在的7个问题及其相关证据并形成推荐建议以指导实践:问题1:对已知原发病因或高度怀疑的恶性胸腔积液,应该在超声引导下行胸腔操作吗?推荐意见:尽管尚无关于恶性胸腔积液的随机对照试验证实超声引导有利于减少气胸、出血等并发症,鉴于超

Baidu
map
Baidu
map
Baidu
map